Niet gecategoriseerd

24 June 2024 We would like to congratulate our partners from the CanNanoVac consortium, the lab of Joke den Haan, with their latest publication on targeting Siglec1 with sdAb-decorated liposomes. This work not only illustrates the application of sdAbs as targeting ligands on liposomes, it also showcases QVQs ability to generate lead molecules against heavily glycosylated targets. In addition, the paper describes our anti-DC-SIGN product Q94c and anti-HIV gp120 product Q1c. Please visit our product page for more sdAb reagents.

24 June 2024 Looking for something interesting to listen to while you unwind on vacation? Josh Clark and Chuck Bryant of the Stuff You Should Know podcast have you covered! In a recent episode, they delve into the history and funny facts of camelids, with a special focus on llamas.But that’s not all — they also explore the uniqueness of single-domain antibodies (sdAbs) and highlight our broad-neutralizing anti-HIV molecules. It’s a perfect blend of entertainment and education to enjoy while you relax.Our anti-HIV molecules are available on our website!

20 June 2024 Multispectral imaging of 3D patient-derived organoids not only generates beautiful images but also allows for the identification of potential new targets and detection probes to recognize tumor tissue during surgery. This EMBO molecular medicine paper highlights the 3D-imaging capacity of QVQ’s anti-NCAM single domain antibody (sdAb) Q55c, as well as for sdAbs against EGFR and HER2. QVQ offers anti-HER2 (Q17), anti-EGFR (Q44), and other target-specific sdAb probes as unlabeled, cysteine-tagged or directionally labeled reagents.

19 December 2023 Q123, also known as VUN701, a single domain antibody binding human atypical chemokine receptor 3 (aka CXCR7) with nanomolar affinity, is now available for research use.  Generated and characterized by Vladimir Bobkov and Martine Smit’s lab at the VU, its effect on receptor conformation was then investigated with Brian Volkman’s lab at Medical College of Wisconsin. Together, this molecule proved to be a neutral antagonist with nanomolar potencies. The work was published in this Science paper last year.